Navigation Links
FDA Approves New Test To Help Determine if Breast Cancer Patients Are Candidates for Herceptin Treatment
Date:6/14/2011

SILVER SPRING, Md., June 14, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved a new genetic test that will help health care professionals determine if women with breast cancer are HER2-positive and, therefore, candidates for Herceptin (trastuzumab), a commonly used breast cancer treatment.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

The test, called Inform Dual ISH, allows for measurement of the number of copies of the HER2 gene in tumor tissue. The HER2 gene is located on chromosome 17 in human cells. An excessive amount of the protein produced by the gene is found in some types of cancer cells, including breast cancer cells.

The Inform Dual ISH test allows lab personnel to count the number of copies of HER2 genes on chromosome 17 in a small sample of the breast tumor. The sample is stained with chemicals that cause copies of HER2 genes and chromosome 17 to change color. Copies of the HER2 gene appear black and copies of chromosome 17 appear red. These color changes can be seen under a standard microscope.

This feature allows lab personnel to see and count copies of chromosome 17 and HER2 genes on the same slide, similar to HER2 amplification measurements that have traditionally only been available using fluorescence microscopes. The Inform Dual ISH, however, allows lab staff to see the HER2 and chromosome 17 signals directly under a microscope, for longer periods of time.

"When used with other clinical information and laboratory tests, this test can provide health care professionals with additional insight on treatment decisions for patients with breast cancer," said Alberto Gutierrez, Ph.D., director of the Office of In Vitro Diagnostic Device Evaluation and Safety in the FDA's Center for Devices and Radiological Health.

The FDA based its approval of the Inform Dual ISH on a U.S. study involving tumor
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... , 21 de noviembre de 2014 /PRNewswire/ ... ensayos clínicos externalizados y tecnologías eClinical, ha indicado ... de ,seguimiento inteligente, para el seguimiento basado en ... inteligente amplía el concepto del seguimiento basado en ... de las visitas de seguimiento o cambio de ...
(Date:11/22/2014)... -- MEDITE Group acquired by CytoCore, Inc. (OTCBB: CYOE) on ... quarter sales ended September 30, 2014 of $8.7 million ... months ended September 2014 and a $38,000 loss for the ... quarter is usually a seasonable weak period due to the ... many countries worldwide, we are proud to announce record sales ...
(Date:11/22/2014)... 2014 Many power shifts are occurring ... of patients in the biopharmaceutical market is impacting ... than ever, understanding how to effectively acquire, convert, ... essential. According to recent research ... spent about two-thirds of their patient-focused dollars on ...
Breaking Medicine Technology:El 'seguimiento inteligente' consigue un excelente momento 2El 'seguimiento inteligente' consigue un excelente momento 3CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 2CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 3New Report Details Importance of Adopting a "Patient Journey" Framework in Marketing 2
... Dec. 22, 2010 Scott & White Healthcare has ... be the home for a new 143-bed acute care ... Investors and College Station ISD. The ... located at the intersection of Texas Hwy 6 and ...
... 2010 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) ... meeting with the US Food and Drug Administration (FDA) for ... meeting discussions reinforce our position that we have a path ... Arena,s President and Chief Executive Officer. "Based on guidance we ...
Cached Medicine Technology:Scott & White Finalizes College Station Land Deal 2Arena and Eisai Complete End-of-Review Meeting with FDA for Lorcaserin New Drug Application 2Arena and Eisai Complete End-of-Review Meeting with FDA for Lorcaserin New Drug Application 3Arena and Eisai Complete End-of-Review Meeting with FDA for Lorcaserin New Drug Application 4Arena and Eisai Complete End-of-Review Meeting with FDA for Lorcaserin New Drug Application 5
(Date:11/23/2014)... Columbus, OH (PRWEB) November 23, 2014 ... claims on behalf of Ohio and West Virginia residents ... and other health disorders due to drinking C8 ... Plant In Parkersburg, West Virginia. According to the C8 ... because they either worked or lived in at least ...
(Date:11/22/2014)... November 23, 2014 A new AlignLife ... doors in the downtown Greenville area. Dr. Chelsea Sineath, ... , decided to open her own clinic after working ... with the patients. , AlignLife believes that the ... With a focus on chiropractic care and rehabilitation to ...
(Date:11/22/2014)... November 23, 2014 A classic black prom ... the most famous dress suppliers, has unveiled its new items ... dresses are now offered at a big discount, up to ... offer. , The new black prom dresses, made with ... to meet the needs of all customers, the company provides ...
(Date:11/22/2014)... NY (PRWEB) November 22, 2014 ... Goods Administration (TGA) approved it for use “as ... approved and listed within the Therapeutic Goods (Listing) ... , Kyowa Hakko’s Setria® Glutathione will be ... biotech specialist that sources and imports fine chemicals ...
(Date:11/22/2014)... TX (PRWEB) November 22, 2014 ... (ICS) as the complaint that the individual has ... for voiding. The report “Nocturia – Pipeline Review, ... development for Nocturia, complete with comparative analysis at ... of action (MoA), route of administration (RoA) and ...
Breaking Medicine News(10 mins):Health News:40 C8 Lawsuit Claims Filed By Wright & Schulte LLC Alleged Serious Illness Due To C8 Contaminated Water In Ohio And West Virginia 2Health News:40 C8 Lawsuit Claims Filed By Wright & Schulte LLC Alleged Serious Illness Due To C8 Contaminated Water In Ohio And West Virginia 3Health News:40 C8 Lawsuit Claims Filed By Wright & Schulte LLC Alleged Serious Illness Due To C8 Contaminated Water In Ohio And West Virginia 4Health News:AlignLife of Downtown Greenville is Now Open and Accepting New Patients 2Health News:New Black Prom Dresses from BellasDress.com 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4
... order to realize international health goals aiming to improve ... health rights is crucial. In an editorial published this ... PLoS Medicine editors argue that action on maternal ... resources as much as it does access to basic ...
... as hair, nails, sweat glands and mammary glandsare rare ... States, according to a report in the June issue ... JAMA/Archives journals. "Cutaneous appendageal carcinomas are a rare ... that frequently present a diagnostic challenge," the authors write ...
... reveals that patients with diabetes who are hospitalized ... experience longer time in the hospital and are also ... without diabetes., High blood sugar may cause more severe ... by Dr. Ali Parappil of the Department of Respiratory ...
... study , MONDAY, June 21 (HealthDay News) -- Using ear ... receive cochlear implants, a new study finds. , U.S. researchers ... who received ear tubes before cochlear implants. In 46 (59 ... cochlear implantation surgery. In all the other cases, the ear ...
... seem more likely to develop allergies, asthma, study ... who are born vaginally pick up different bacteria than ... how their immune systems develop, a new study suggests. ... why babies born through cesarean sections appear to be ...
... ancient language provides new insights into the nature of ... study, "Dvandvas, Blocking, and the Associative: The Bumpy Ride ... June 2010 issue of the scholarly journal Language, ... A preprint version is available on line at:, http://lsadc.org/info/documents/2010/press-releases/kiparsky.pdf ...
Cached Medicine News:Health News:Cancers of sweat glands, other skin-related structures may be increasing in United States 2Health News:Ear Tubes Appear to Be Safe Before Cochlear Implantation 2Health News:Delivery Method May Determine the Bacteria Babies Acquire 2Health News:Delivery Method May Determine the Bacteria Babies Acquire 3Health News:The 'bumpy ride' of linguistic change 2
Colloidal Gold Sol, 40 nm - 12 - 15, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
... magnification all glass (1.5x) Gonio lens will ... ease., The 4 mirror lens is the ... dynamic gonioscopy and features : , ... appreciate details previously unattainable with Gonio lenses., ...
Colloidal Gold Sol, 20 nm - 50 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
... The PalmScan P2000 Pachymeter [i.e., PalmScan ... portable,battery operated biometer, which incorporates A-mode ... used to accurately measure the corneal ... human eyes. PalmScan P2000 includes two ...
Medicine Products: